_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
502912814,7/14/2014 12:51:18,,1322815609,7/14/2014 12:51:12,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],common,da,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 13:07:06,,1322826079,7/14/2014 13:06:29,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],side effect of,N/A,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 13:22:48,,1322836963,7/14/2014 13:22:35,clixsense,1,6500439,AUS,02,Ingleburn,115.146.65.99,[SIDE_EFFECT],[SIDE_EFFECT],common side effect of,n/a,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 13:27:18,,1322839985,7/14/2014 13:26:16,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,[SIDE_EFFECT],[SIDE_EFFECT],common side effect,na,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 13:36:35,,1322846585,7/14/2014 13:36:21,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[SIDE_EFFECT],[SIDE_EFFECT],side effect,N/A,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 13:42:20,,1322850716,7/14/2014 13:41:55,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],is a side effect,N/A,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 13:45:57,,1322853292,7/14/2014 13:45:02,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SIDE_EFFECT],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",common side effect,n/a,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 14:01:46,,1322864631,7/14/2014 14:00:48,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT],[SIDE_EFFECT],common side effect of,n/a,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 14:07:03,,1322868164,7/14/2014 14:06:32,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SIDE_EFFECT],[SIDE_EFFECT],TARDIVE DYSKINESIA (TD) LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,n/a,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 14:08:47,,1322869214,7/14/2014 14:08:24,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SIDE_EFFECT],[SIDE_EFFECT],common side effect,Na,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 14:09:17,,1322869545,7/14/2014 14:09:05,instagc,1.0,18960682,GBR,"","",86.29.147.112,[SIDE_EFFECT],[SIDE_EFFECT],is a common side effect,N/a,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 14:20:49,,1322877444,7/14/2014 14:20:20,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SIDE_EFFECT],[SIDE_EFFECT],is a common side effect of,N/A,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 14:24:29,,1322879943,7/14/2014 14:24:18,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],MEDICATION,N/A,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 14:27:29,,1322882167,7/14/2014 14:27:00,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[SIDE_EFFECT],[SIDE_EFFECT],is a common side effect,N/A,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912814,7/14/2014 14:38:24,,1322889916,7/14/2014 14:38:17,instagc,1,27753923,GBR,"","",188.30.192.65,[CAUSES],[CAUSES],TARDIVE DYSKINESIA,n/a,51,0,96,18,1,RO-has_causative_agent,903749-FS1,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
502912815,7/14/2014 13:01:56,,1322822743,7/14/2014 13:01:16,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],as well as normal,N/A,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 13:09:22,,1322827724,7/14/2014 13:08:50,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],normal,N/A,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 13:16:31,,1322832652,7/14/2014 13:16:02,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[IS_A],[IS_A],as well as normal,n/a,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 13:24:51,,1322838309,7/14/2014 13:24:00,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[LOCATION] [ASSOCIATED_WITH],"[LOCATION]
[ASSOCIATED_WITH]",as well as,na,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 13:31:36,,1322842817,7/14/2014 13:30:53,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"By contrast,",N/A,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 13:37:57,,1322847542,7/14/2014 13:37:12,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],as well as,none,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 14:03:22,,1322865764,7/14/2014 14:03:05,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as normal,n/a,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 14:06:19,,1322867701,7/14/2014 14:06:05,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SIDE_EFFECT],[SIDE_EFFECT],as well,Na,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 14:18:31,,1322875681,7/14/2014 14:17:56,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHRONIC GRANULOCYTIC LEUKEMIA CELLS BONE MARROW CELLS,n/a,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 14:27:53,,1322882468,7/14/2014 14:27:45,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LEUKEMIA,N/A,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 14:29:44,,1322883909,7/14/2014 14:29:25,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,N/A,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 14:33:58,,1322886908,7/14/2014 14:32:33,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS,N/A,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 14:49:11,,1322896824,7/14/2014 14:48:08,clixsense,1,19294877,USA,MA,Boston,140.241.0.20,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as BONE MARROW CELLS,N/A,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 14:52:52,,1322899107,7/14/2014 14:52:23,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[SYMPTOM] [ASSOCIATED_WITH] [SIDE_EFFECT],"[SYMPTOM]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",as well as normal,[SYMPTOM] [ASSOCIATED_WITH] [SIDE_EFFECT],67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912815,7/14/2014 14:53:58,,1322899683,7/14/2014 14:53:40,rewardsspot,1,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHRONIC GRANULOCYTIC LEUKEMIA CELLS BONE MARROW CELLS,n/a,67,13,83,48,1,RO-disease_has_primary_anatomic_site,902419-FS1,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS
502912816,7/14/2014 12:50:41,,1322815171,7/14/2014 12:50:35,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],"inflammatory,",da,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 13:06:20,,1322825560,7/14/2014 13:06:00,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],described with,Na,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 13:29:32,,1322841478,7/14/2014 13:28:56,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],are described,N/A,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 13:30:43,,1322842293,7/14/2014 13:30:19,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PART_OF],[PART_OF],respect,N/A,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 13:32:20,,1322843325,7/14/2014 13:31:33,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[IS_A],[IS_A],respect to shape and size of,na,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 14:04:50,,1322866694,7/14/2014 14:04:32,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",respect to shape and size of,n/a,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 14:10:48,,1322870485,7/14/2014 14:10:27,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],are described with respect to shape and size of,N/a,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 14:20:20,,1322876999,7/14/2014 14:19:30,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],are described with respect to shape and size of,N/A,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 14:26:53,,1322881735,7/14/2014 14:26:41,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],INTESTINAL,N/A,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 14:27:10,,1322881915,7/14/2014 14:26:33,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[IS_A] [ASSOCIATED_WITH] [PART_OF] [TREATS],"[TREATS]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",described size,na,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 14:28:37,,1322883076,7/14/2014 14:28:18,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[PART_OF],[PART_OF],described with respect,N/A,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 14:42:09,,1322892524,7/14/2014 14:40:58,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],are described with respect to shape and size of,N/A,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 14:49:21,,1322896920,7/14/2014 14:46:57,neodev,1,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],are described with respect to shape and size of,N/A,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 14:50:22,,1322897572,7/14/2014 14:49:56,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GASTRO INTESTINAL POLYPS POLYPOID LESION,n/a,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912816,7/14/2014 14:51:25,,1322898183,7/14/2014 14:49:54,clixsense,1,21406414,USA,NY,Spencerport,50.122.189.231,[MANIFESTATION],[MANIFESTATION],described with respect to,they are part of,106,33,120,57,-1,RO-disease_has_finding,901529-FS1,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
502912817,7/14/2014 12:53:10,,1322816928,7/14/2014 12:53:00,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[SYMPTOM],[SYMPTOM],adjunctive,da,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 13:10:35,,1322828574,7/14/2014 13:10:12,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],who are receiving,n/a,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 13:23:07,,1322837255,7/14/2014 13:22:34,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[PART_OF],[PART_OF],receiving,none,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 13:25:50,,1322838984,7/14/2014 13:25:27,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],are receiving,N/A,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 13:34:36,,1322845110,7/14/2014 13:34:24,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],receiving,N/A,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 13:35:03,,1322845371,7/14/2014 13:34:15,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],useful option in patients,na,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 14:06:27,,1322867779,7/14/2014 14:05:46,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],FLUCTUATING PARKINSON'S DISEASE LEVODOPA/DDCI,n/a,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 14:07:15,,1322868329,7/14/2014 14:07:02,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],who are receiving,N/a,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 14:17:47,,1322875273,7/14/2014 14:16:29,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],who are receiving,N/A,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 14:18:36,,1322875801,7/14/2014 14:17:55,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],who are receiving,N/A,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 14:23:03,,1322878931,7/14/2014 14:22:52,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CONTRAINDICATES],[CONTRAINDICATES],FLUCTUATING,N/A,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 14:31:05,,1322884901,7/14/2014 14:30:47,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],who are receiving,N/A,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 14:32:03,,1322885670,7/14/2014 14:31:32,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],"candidates for,",na,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 14:43:17,,1322893200,7/14/2014 14:42:00,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[TREATS],[TREATS],is useful in patients with FLUCTUATING PARKINSON'S DISEASE LEVODOPA/DDCI treatments.,N/A,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912817,7/14/2014 14:44:34,,1322894117,7/14/2014 14:44:29,instagc,1.0,27753923,GBR,"","",188.30.192.65,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],FLUCTUATING PARKINSON'S,n/a,52,102,82,115,1,RO-may_treat,908084-FS1,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
502912818,7/14/2014 12:53:27,,1322817138,7/14/2014 12:53:19,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],cyclosporine,da,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 13:08:17,,1322826991,7/14/2014 13:08:03,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],done with,Na,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 13:11:30,,1322829109,7/14/2014 13:11:04,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],done with,N/A,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 13:21:25,,1322835913,7/14/2014 13:20:44,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],was done,N/A,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 13:21:53,,1322836237,7/14/2014 13:21:25,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,none,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 13:35:06,,1322845396,7/14/2014 13:34:52,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],done,N/A,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 13:37:21,,1322847079,7/14/2014 13:36:46,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],was done with,na,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 13:55:58,,1322860645,7/14/2014 13:53:55,clixsense,1.0,19294877,USA,MA,Boston,140.241.0.20,[TREATS],[TREATS],GVHD PROPHYLAXIS was done with (CYA,N/A,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 14:07:23,,1322868384,7/14/2014 14:07:05,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was done with cyclosporine,n/a,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 14:17:22,,1322875008,7/14/2014 14:16:46,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],was done with,N/A,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 14:19:00,,1322876079,7/14/2014 14:18:43,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[TREATS],[TREATS],GVHD PROPHYLAXIS (CYA METHOTREXATE AND PREDNISONE,N/A,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 14:19:12,,1322876278,7/14/2014 14:18:36,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GVHD PROPHYLAXIS (CYA METHOTREXATE AND PREDNISONE (PDN.,n/a,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 14:23:26,,1322879172,7/14/2014 14:22:46,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],with cyclosporine,na,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 14:29:12,,1322883435,7/14/2014 14:29:04,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],METHOTREXATE,N/A,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912818,7/14/2014 14:40:04,,1322891080,7/14/2014 14:39:54,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CONTRAINDICATES],[CONTRAINDICATES],GVHD PROPHYLAXIS,n/a,0,44,15,81,1,RO-may_treat,908161-FS1,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN
502912819,7/14/2014 13:05:07,,1322824707,7/14/2014 13:04:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],DRUG RESISTANT,N/A,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 13:19:28,,1322834474,7/14/2014 13:19:02,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],"actually available, the problem of",n/a,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 13:31:58,,1322843049,7/14/2014 13:31:35,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],problem,N/A,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 13:35:06,,1322845398,7/14/2014 13:34:41,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],problem,none,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 13:41:54,,1322850338,7/14/2014 13:41:25,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],has not been solved.,N/A,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 14:03:00,,1322865522,7/14/2014 14:00:57,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the problem of,N/A,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 14:06:31,,1322867820,7/14/2014 14:06:13,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]","actually available,",N/a,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 14:11:48,,1322871129,7/14/2014 14:11:14,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANTIEPILEPTIC DRUGS (AEDS) DRUG RESISTANT EPILEPSY,n/a,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 14:23:13,,1322879049,7/14/2014 14:22:44,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],the problem of,N/A,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 14:32:58,,1322886307,7/14/2014 14:32:24,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANTIEPILEPTIC DRUGS DRUG RESISTANT,N/A,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 14:45:59,,1322895010,7/14/2014 14:44:51,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],problem,na,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 14:52:36,,1322898920,7/14/2014 14:52:04,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],ANTIEPILEPTIC DRUGS EPILEPSY,N/A,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 14:53:03,,1322899200,7/14/2014 14:52:38,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ANTIEPILEPTIC DRUGS (AEDS) DRUG RESISTANT EPILEPSY,n/a,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 14:53:43,,1322899577,7/14/2014 14:53:03,clixsense,1.0,19294877,USA,MA,Boston,140.241.0.20,[TREATS],[TREATS],"ANTIEPILEPTIC DRUGS available, problem DRUG RESISTANT EPILEPSY",N/A,94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912819,7/14/2014 14:54:20,,1322899884,7/14/2014 14:53:58,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[PREVENTS] [DIAGNOSE_BY_TEST_OR_DRUG],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]","actually available,",[PREVENTS] [DIAGNOSE_BY_TEST_OR_DRUG],94,32,116,58,1,RO-may_treat,908168-FS1,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
502912820,7/14/2014 12:52:43,,1322816598,7/14/2014 12:52:36,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],function,da,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 13:04:10,,1322824203,7/14/2014 13:03:18,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],associated with,N/A,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 13:10:11,,1322828332,7/14/2014 13:09:48,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 13:31:03,,1322842499,7/14/2014 13:30:27,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,none,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 13:37:56,,1322847521,7/14/2014 13:37:39,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 13:40:36,,1322849503,7/14/2014 13:40:10,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has been associated with,na,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 13:51:32,,1322857577,7/14/2014 13:50:28,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has not been totally,n/a,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 14:02:07,,1322864869,7/14/2014 14:01:48,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 14:06:04,,1322867481,7/14/2014 14:05:49,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],associated,Na,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 14:07:36,,1322868555,7/14/2014 14:07:16,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],been associated with,N/a,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 14:19:54,,1322876748,7/14/2014 14:19:35,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],OCA2 OCA2 SKIN AND HAIR PIGMENTATION,N/A,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 14:20:30,,1322877149,7/14/2014 14:19:57,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],OCA2 SKIN AND HAIR PIGMENTATION,n/a,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 14:24:54,,1322880297,7/14/2014 14:23:47,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human,N/A,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 14:25:37,,1322880895,7/14/2014 14:24:45,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has been associated with,N/A,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912820,7/14/2014 14:26:21,,1322881367,7/14/2014 14:26:11,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],variation,N/A,122,29,147,33,1,RO-has_finding_site,905331-FS1,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
502912821,7/14/2014 12:51:11,,1322815524,7/14/2014 12:51:04,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[LOCATION],[LOCATION],used,da,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 13:01:12,,1322822264,7/14/2014 13:00:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],selecting and storing the BACTERIA,N/A,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 13:11:42,,1322829329,7/14/2014 13:11:07,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[IS_A],[IS_A],experimental model in selecting and storing the,n/a,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 13:28:18,,1322840639,7/14/2014 13:27:23,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],can be used,N/A,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 13:29:03,,1322841145,7/14/2014 13:28:37,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[LOCATION],[LOCATION],selecting and storing the,na,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 13:35:31,,1322845738,7/14/2014 13:35:07,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],selecting and storing,N/A,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 13:36:46,,1322846688,7/14/2014 13:36:14,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],used,none,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 14:02:37,,1322865230,7/14/2014 14:02:12,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],the,N/a,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 14:19:29,,1322876440,7/14/2014 14:18:37,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",provided that great care taken in selecting storing the,N/A,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 14:20:14,,1322876945,7/14/2014 14:19:08,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],provided that great care is taken in selecting and storing the,N/A,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 14:21:11,,1322877660,7/14/2014 14:20:58,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CONTRAINDICATES],[CONTRAINDICATES],CARIES,N/A,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 14:22:38,,1322878662,7/14/2014 14:22:02,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CARIES BACTERIA,n/a,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 14:35:36,,1322887990,7/14/2014 14:35:17,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],experimental model,N/A,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 14:39:52,,1322890966,7/14/2014 14:39:46,instagc,1.0,27753923,GBR,"","",188.30.192.65,[PREVENTS],[PREVENTS],Hence Balb/c,n/a,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912821,7/14/2014 14:48:00,,1322896203,7/14/2014 14:47:43,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CARIES BACTERIA,n/a,138,58,145,64,-1,RO-has_causative_agent,903870-FS1,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES
502912822,7/14/2014 12:51:48,,1322816026,7/14/2014 12:51:43,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],pain:,da,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 13:02:41,,1322823225,7/14/2014 13:01:57,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",was effective in,N/A,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 13:06:44,,1322825858,7/14/2014 13:06:34,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],effective,Na,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 13:18:14,,1322833723,7/14/2014 13:17:52,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],effective in 3 of 4 trials in,n/a,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 13:29:50,,1322841702,7/14/2014 13:29:05,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],effective in 3 of 4 trials,na,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 13:32:01,,1322843058,7/14/2014 13:31:37,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],was effective,N/A,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 13:36:11,,1322846218,7/14/2014 13:35:38,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],effective,none,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 13:54:08,,1322859370,7/14/2014 13:53:26,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SIDE_EFFECT],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",3 of 4 trials,n/a,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 14:06:46,,1322867986,7/14/2014 14:06:32,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],was effective in 3 of 4 trials,N/a,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 14:09:47,,1322869807,7/14/2014 14:07:57,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[NONE],[NONE],N/A,carbenezaoine treats the first not the other way around,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 14:10:32,,1322870274,7/14/2014 14:09:56,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],CARBAMAZEPINE TRIGEMINAL NEURALGIA,n/a,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 14:28:52,,1322883205,7/14/2014 14:28:38,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],was effective,N/A,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 14:30:12,,1322884316,7/14/2014 14:29:37,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],was effective in 3 of 4 trials in,N/A,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 14:44:03,,1322893791,7/14/2014 14:43:47,instagc,1.0,27753923,GBR,"","",188.30.192.65,[PREVENTS],[PREVENTS],CARBAMAZEPINE effective,n/a,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912822,7/14/2014 14:46:09,,1322895131,7/14/2014 14:44:59,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[TREATS],[TREATS],CARBAMAZEPINE was effective in TRIGEMINAL NEURALGIA,N/A,83,35,102,48,1,RO-may_treat,907754-FS1,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
502912823,7/14/2014 13:08:09,,1322826902,7/14/2014 13:07:47,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],POLYP,N/A,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 13:12:59,,1322830193,7/14/2014 13:12:05,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[IS_A],[IS_A],presenting as,n/a,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 13:25:26,,1322838712,7/14/2014 13:24:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],have established diagnosis,N/A,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 13:29:57,,1322841797,7/14/2014 13:29:32,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[SYMPTOM],[SYMPTOM],presenting,none,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 13:45:15,,1322852763,7/14/2014 13:44:39,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"in three patients, and a single in the fourth patient.",na,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 13:52:52,,1322858512,7/14/2014 13:51:35,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"three patients,",n/a,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 14:01:51,,1322864655,7/14/2014 14:01:26,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],presenting as,N/a,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 14:07:19,,1322868373,7/14/2014 14:07:05,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],single,Na,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 14:11:34,,1322870976,7/14/2014 14:10:38,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[IS_A],[IS_A],MULTIPLE and single,N/A,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 14:18:42,,1322875867,7/14/2014 14:16:36,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[SYMPTOM],[SYMPTOM],non secretory gastric carcinoid of the body and fundus presenting MULTIPLE POLYPS and POLYP MASS,N/A,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 14:23:15,,1322879072,7/14/2014 14:23:04,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],POLYP,N/A,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 14:26:59,,1322881847,7/14/2014 14:26:22,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],MULTIPLE POLYPS POLYP MASS,N/A,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 14:32:38,,1322886021,7/14/2014 14:32:04,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],"patients, single",na,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 14:42:56,,1322892997,7/14/2014 14:42:48,instagc,1.0,27753923,GBR,"","",188.30.192.65,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],POLYP MASS,n/a,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912823,7/14/2014 14:49:04,,1322896785,7/14/2014 14:48:44,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MULTIPLE POLYPS POLYP MASS,n/a,180,132,189,147,-1,RO-disease_may_have_finding,902584-FS1,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS
502912824,7/14/2014 12:51:56,,1322816116,7/14/2014 12:51:49,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],Epoetin,da,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 13:11:02,,1322828800,7/14/2014 13:10:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],receiving,N/A,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 13:13:48,,1322830772,7/14/2014 13:13:23,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],Therapy Treatment of patients receiving,n/a,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 13:21:23,,1322835888,7/14/2014 13:20:41,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],in,none,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 14:09:13,,1322869474,7/14/2014 14:08:59,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],hemodialysis patients,Na,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 14:11:02,,1322870704,7/14/2014 14:10:49,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],in hemodialysis patients receiving,N/a,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 14:17:47,,1322875276,7/14/2014 14:17:32,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[PREVENTS],[PREVENTS],IRON DEFICIENCY ANEMIA EPOETIN ALFA THERAPY.,N/A,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 14:19:06,,1322876185,7/14/2014 14:17:47,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],in hemodialysis patients receiving,N/A,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 14:23:46,,1322879438,7/14/2014 14:22:05,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[TREATS],[TREATS],Saccharated Ferric Oxide Uses Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,N/A,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 14:27:34,,1322882245,7/14/2014 14:27:23,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],ANEMIA,N/A,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 14:31:31,,1322885288,7/14/2014 14:30:55,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],patients receiving,na,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 14:36:45,,1322888753,7/14/2014 14:36:28,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],receiving,N/A,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 14:37:11,,1322889104,7/14/2014 14:37:05,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CAUSES],[CAUSES],Therapy Treatment,n/a,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 14:51:51,,1322898362,7/14/2014 14:51:29,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[TREATS],[TREATS],Therapy Treatment,[TREATS],210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912824,7/14/2014 14:51:52,,1322898410,7/14/2014 14:51:11,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[SIDE_EFFECT],[SIDE_EFFECT],patients receiving EPOETIN ALFA THERAPY.,N/A,210,268,231,288,1,RO-may_treat,907636-FS1,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
502912825,7/14/2014 12:52:12,,1322816309,7/14/2014 12:52:06,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INTERSTITIAL,da,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 13:07:15,,1322826215,7/14/2014 13:07:02,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],used,Na,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 13:19:00,,1322834222,7/14/2014 13:18:44,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],has been used for,n/a,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 13:35:51,,1322845975,7/14/2014 13:35:03,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],has been used for,na,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 13:38:18,,1322847725,7/14/2014 13:37:59,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],used,none,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 14:13:14,,1322872306,7/14/2014 14:12:50,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],has been used for,n/a,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 14:13:49,,1322872694,7/14/2014 14:13:15,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,n/a,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 14:16:44,,1322874565,7/14/2014 14:16:17,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],has been used for,N/A,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 14:20:07,,1322876852,7/14/2014 14:19:55,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[LOCATION],[LOCATION],PERCUTANEOUS,N/A,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 14:25:30,,1322880785,7/14/2014 14:25:17,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],PERCUTANEOUS,N/A,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 14:27:43,,1322882331,7/14/2014 14:27:11,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],used,na,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 14:41:58,,1322892394,7/14/2014 14:41:46,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CAUSES],[CAUSES],RADIOFREQUENCY INTERSTITIAL,n/a,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 14:48:52,,1322896706,7/14/2014 14:46:57,clixsense,1.0,21406414,USA,NY,Spencerport,50.122.189.231,[TREATS],[TREATS],used for,used for suggests a treatment,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 14:50:57,,1322897920,7/14/2014 14:50:24,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA PERCUTANEOUS ABLATION OF HEPATOCELLULAR,n/a,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912825,7/14/2014 14:51:09,,1322898029,7/14/2014 14:49:58,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[TREATS],[TREATS],RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA in local anesthesia.,N/A,0,59,39,108,-1,RO-disease_may_have_finding,902788-FS1,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA
502912826,7/14/2014 13:24:58,,1322838392,7/14/2014 13:24:18,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was to investigate,N/A,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 13:31:16,,1322842602,7/14/2014 13:31:00,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 13:33:30,,1322844293,7/14/2014 13:32:54,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],interaction,none,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 13:41:36,,1322850152,7/14/2014 13:41:07,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 14:04:12,,1322866253,7/14/2014 14:03:14,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NICOTINE DEPENDENCE NICOTINE AND COTININE LEVELS,n/a,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 14:07:50,,1322868691,7/14/2014 14:07:37,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],interaction variation,Na,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 14:08:35,,1322869144,7/14/2014 14:08:12,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],in relation to,N/a,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 14:10:53,,1322870576,7/14/2014 14:10:36,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relation,n/a,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 14:12:54,,1322872051,7/14/2014 14:12:12,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],and,N/A,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 14:19:54,,1322876733,7/14/2014 14:18:43,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigate NICOTINE DEPENDENCE NICOTINE AND COTININE LEVELS in hair samples.,N/A,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 14:26:30,,1322881474,7/14/2014 14:26:22,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],AND,N/A,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 14:32:37,,1322886004,7/14/2014 14:30:13,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 14:33:11,,1322886432,7/14/2014 14:32:40,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",in hair samples.,NA,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 14:36:27,,1322888577,7/14/2014 14:36:08,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NICOTINE NICOTINE,N/A,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912826,7/14/2014 14:39:05,,1322890357,7/14/2014 14:38:57,instagc,1.0,27753923,GBR,"","",188.30.192.65,[MANIFESTATION],[MANIFESTATION],NICOTINE DEPENDENCE,n/a,184,160,211,179,-1,RO-has_causative_agent,903879-FS1,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE
502912827,7/14/2014 12:52:59,,1322816835,7/14/2014 12:52:53,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],FUNGOIDES,da,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 12:57:04,,1322819529,7/14/2014 12:55:39,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 13:07:01,,1322826019,7/14/2014 13:06:46,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 13:26:40,,1322839546,7/14/2014 13:26:03,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[OTHER],[OTHER],Excluding,none,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 13:36:20,,1322846384,7/14/2014 13:36:05,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 13:53:24,,1322858926,7/14/2014 13:52:54,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 14:10:00,,1322869911,7/14/2014 14:09:43,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and 4 cases,N/a,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 14:10:36,,1322870351,7/14/2014 14:09:48,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],Excluding of and of,N/A,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 14:11:12,,1322870766,7/14/2014 14:10:54,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],classified,n/a,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 14:17:31,,1322875085,7/14/2014 14:17:17,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[TREATS],[TREATS],MYCOSIS FUNGOIDES CUTANEOUS INVOLVEMENT,N/A,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 14:25:46,,1322880991,7/14/2014 14:23:58,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],4 cases and,na,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 14:44:16,,1322893942,7/14/2014 14:44:04,instagc,1.0,27753923,GBR,"","",188.30.192.65,[MANIFESTATION],[MANIFESTATION],MYCOSIS FUNGOIDES,n/a,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 14:52:36,,1322898940,7/14/2014 14:52:18,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MYCOSIS FUNGOIDES CUTANEOUS INVOLVEMENT,n/a,55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 14:53:12,,1322899290,7/14/2014 14:51:52,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[NONE],[NONE],N/A,"Two separate conditions observed in patients, noting more.",55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912827,7/14/2014 14:53:23,,1322899377,7/14/2014 14:52:55,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],4 cases of,[CAUSES],55,22,75,39,-1,RO-disease_has_finding,901536-FS1,"Excluding 13 cases of MYCOSIS FUNGOIDES and 4 cases of CUTANEOUS INVOLVEMENT of proven adult T cell lymphoma/leukemia, the remaining 32 cases were further classified according to their pathological and clinical features.",CUTANEOUS INVOLVEMENT,MYCOSIS FUNGOIDES
502912828,7/14/2014 12:50:07,,1322814784,7/14/2014 12:49:58,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],births,da,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 13:00:27,,1322821808,7/14/2014 12:59:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],RESPIRATORY DISTRESS,N/A,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 13:04:58,,1322824667,7/14/2014 13:04:46,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SIDE_EFFECT],[SIDE_EFFECT],as,Na,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 13:20:54,,1322835474,7/14/2014 13:20:21,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],misclassification of cases of RESPIRATORY DISTRESS SYNDROME;,n/a,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 13:31:47,,1322842959,7/14/2014 13:31:07,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],misclassification,none,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 13:34:04,,1322844640,7/14/2014 13:33:36,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as,N/A,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 13:34:12,,1322844832,7/14/2014 13:33:11,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as,na,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 13:40:03,,1322849071,7/14/2014 13:39:18,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],association was not explained by,N/A,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 13:57:53,,1322861858,7/14/2014 13:56:45,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],cases of as,N/A,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 14:01:27,,1322864447,7/14/2014 14:00:44,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],MILD TRANSIENT RESPIRATORY DISTRESS RESPIRATORY DISTRESS SYNDROME;,n/a,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 14:09:04,,1322869386,7/14/2014 14:08:36,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],misclassification of cases,N/a,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 14:12:14,,1322871534,7/14/2014 14:11:13,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],association,n/a,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 14:26:01,,1322881111,7/14/2014 14:25:51,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],elective,N/A,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 14:27:56,,1322882502,7/14/2014 14:27:34,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],misclassification,N/A,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912828,7/14/2014 14:37:15,,1322889123,7/14/2014 14:36:32,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],common after Cesarean birth),na,122,209,156,238,-1,RO-disease_has_finding,901937-FS1,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
502912829,7/14/2014 13:08:49,,1322827308,7/14/2014 13:08:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],caused by,N/A,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 13:16:47,,1322832792,7/14/2014 13:16:33,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],caused by,n/a,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 13:25:28,,1322838707,7/14/2014 13:24:57,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[CAUSES],[CAUSES],caused,none,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 13:33:10,,1322844101,7/14/2014 13:32:23,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],caused by,na,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 13:39:09,,1322848429,7/14/2014 13:38:57,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[CAUSES],[CAUSES],caused,N/A,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 14:00:56,,1322864013,7/14/2014 14:00:20,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SIDE_EFFECT],[SIDE_EFFECT],caused by,N/A,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 14:05:25,,1322866995,7/14/2014 14:05:13,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],caused,n/a,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 14:05:48,,1322867279,7/14/2014 14:05:34,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],caused,Na,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 14:15:43,,1322873970,7/14/2014 14:14:35,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],PELVIC PAIN ENDOMETRIOSIS,n/a,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 14:25:54,,1322881075,7/14/2014 14:24:55,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[CONTRAINDICATES],[CONTRAINDICATES],not approved for the treatment of PELVIC PAIN ENDOMETRIOSIS,N/A,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 14:28:12,,1322882674,7/14/2014 14:28:04,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],treatment,N/A,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 14:40:11,,1322891188,7/14/2014 14:40:05,instagc,1.0,27753923,GBR,"","",188.30.192.65,[SYMPTOM],[SYMPTOM],Aromatase inhibitors,n/a,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 14:40:26,,1322891359,7/14/2014 14:37:42,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],caused by,N/A,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 14:44:51,,1322894272,7/14/2014 14:43:20,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],caused by,na,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912829,7/14/2014 14:48:42,,1322896604,7/14/2014 14:48:21,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[CAUSES],[CAUSES],PELVIC PAIN ENDOMETRIOSIS,n/a,64,86,74,99,-1,RO-has_definitional_manifestation,904571-FS1,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
502912830,7/14/2014 12:50:34,,1322815085,7/14/2014 12:50:26,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],common,da,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 13:13:44,,1322830699,7/14/2014 13:13:19,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[MANIFESTATION] [CAUSES],"[CAUSES]
[MANIFESTATION]",characterized by,N/A,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 13:17:51,,1322833493,7/14/2014 13:17:30,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],characterized by,n/a,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 13:24:53,,1322838338,7/14/2014 13:24:24,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],condition,none,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 13:31:28,,1322842720,7/14/2014 13:30:55,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],characterized by,na,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 13:42:49,,1322851041,7/14/2014 13:42:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],is characterized by,N/A,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 14:07:50,,1322868690,7/14/2014 14:07:37,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],characterized by benign,N/a,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 14:13:10,,1322872227,7/14/2014 14:12:34,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],NEUROFIBROMATOSIS TYPE 1 (NF1) TUMOR (NEUROFIBROMA),n/a,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 14:13:34,,1322872574,7/14/2014 14:12:56,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],is a common condition characterized by benign,N/A,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 14:17:16,,1322874900,7/14/2014 14:17:00,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[PREVENTS],[PREVENTS],NEUROFIBROMATOSIS TYPE 1 TUMOR (NEUROFIBROMA),N/A,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 14:34:06,,1322886977,7/14/2014 14:32:38,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],condition characterized by benign,N/A,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 14:35:16,,1322887786,7/14/2014 14:34:59,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[SYMPTOM],[SYMPTOM],characterized,N/A,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 14:38:39,,1322890111,7/14/2014 14:38:26,instagc,1.0,27753923,GBR,"","",188.30.192.65,[LOCATION],[LOCATION],NEUROFIBROMATOSIS TYPE,n/a,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 14:39:09,,1322890428,7/14/2014 14:37:36,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NEUROFIBROMATOSIS TYPE 1 characterized by benign TUMOR (NEUROFIBROMA),N/A,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912830,7/14/2014 14:41:41,,1322891930,7/14/2014 14:40:47,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],dominant condition,na,96,0,114,24,1,RO-has_manifestation,906112-FS1,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
502912831,7/14/2014 12:49:49,,1322814576,7/14/2014 12:49:39,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CONTRAINDICATES],[CONTRAINDICATES],"headache,",da,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 13:03:17,,1322823663,7/14/2014 13:02:12,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],classification:,N/A,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 13:05:43,,1322825138,7/14/2014 13:05:30,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],inclusion,Na,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 13:15:14,,1322831694,7/14/2014 13:14:51,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],inclusion of a number of,n/a,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 13:34:51,,1322845246,7/14/2014 13:34:37,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PART_OF],[PART_OF],inclusion,N/A,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 13:39:16,,1322848518,7/14/2014 13:38:46,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],compared with,N/A,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 13:44:00,,1322851970,7/14/2014 13:43:20,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"secondary headaches,",na,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 14:02:19,,1322865007,7/14/2014 14:01:32,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHRONIC MIGRAINE NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,n/a,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 14:07:56,,1322868739,7/14/2014 14:07:23,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],inclusion of a number of,N/A,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 14:18:05,,1322875515,7/14/2014 14:17:48,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[PREVENTS],[PREVENTS],CHRONIC MIGRAINE NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,N/A,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 14:27:22,,1322882117,7/14/2014 14:27:14,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[LOCATION],[LOCATION],"continua),",N/A,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 14:31:07,,1322884922,7/14/2014 14:29:28,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]","better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE and",N/A,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 14:33:20,,1322886504,7/14/2014 14:32:59,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[PART_OF],[PART_OF],inclusion of a number,N/A,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 14:37:03,,1322888983,7/14/2014 14:36:53,instagc,1.0,27753923,GBR,"","",188.30.192.65,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],number NEW,n/a,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912831,7/14/2014 14:43:16,,1322893197,7/14/2014 14:42:38,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],"new daily persistent headache,",na,228,186,271,202,-1,RO-has_definitional_manifestation,904573-FS1,"This article summarizes the main new features of ICHD II, compared with the original International Headache Society classification: better definition of migraine with aura, inclusion of CHRONIC MIGRAINE inclusion of a number of NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE benign thunderclap headache, new daily persistent headache, hemicrania continua), better definition of the secondary headaches, introduction of medication overuse headache and of headache attributed to psychiatric disorder.",NEW PRIMARY HEADACHES (SUNCT HYPNIC HEADACHE,CHRONIC MIGRAINE
502912832,7/14/2014 13:16:00,,1322832210,7/14/2014 13:15:36,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],might explain that TDI induces,n/a,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 13:16:49,,1322832815,7/14/2014 13:15:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 13:33:36,,1322844333,7/14/2014 13:33:17,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[CAUSES],[CAUSES],induces,N/A,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 13:34:04,,1322844633,7/14/2014 13:33:31,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],led,none,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 13:37:11,,1322846954,7/14/2014 13:36:26,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],induces,N/A,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 13:43:18,,1322851460,7/14/2014 13:42:36,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared to,na,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 14:04:53,,1322866735,7/14/2014 14:04:17,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],that might explain,N/A,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 14:10:34,,1322870300,7/14/2014 14:10:11,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],induces,n/a,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 14:21:14,,1322877684,7/14/2014 14:20:36,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SINGLE METHACHOLINE STIMULATION BRONCHIAL HYPERREACTIVITY,n/a,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 14:24:41,,1322880191,7/14/2014 14:24:31,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],methacholine,N/A,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 14:26:20,,1322881363,7/14/2014 14:25:45,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],compared,N/A,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 14:29:36,,1322883784,7/14/2014 14:28:17,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],that might explain that TDI induces,N/A,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 14:38:12,,1322889764,7/14/2014 14:37:15,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],compared to,na,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 14:38:56,,1322890280,7/14/2014 14:38:50,instagc,1.0,27753923,GBR,"","",188.30.192.65,[LOCATION],[LOCATION],"extracellular Ca(2+),",n/a,201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912832,7/14/2014 14:49:55,,1322897311,7/14/2014 14:49:31,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],induces,[ASSOCIATED_WITH],201,133,225,164,1,RO-may_diagnose,906678-FS1,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
502912833,7/14/2014 12:50:15,,1322814847,7/14/2014 12:50:07,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INFLAMMATORY,da,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 13:08:01,,1322826821,7/14/2014 13:07:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],unclear.,Na,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 13:12:05,,1322829512,7/14/2014 13:11:44,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],pathophysiological function in,n/a,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 13:15:47,,1322832098,7/14/2014 13:15:07,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 13:30:52,,1322842395,7/14/2014 13:29:34,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],is induced,N/A,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 13:32:46,,1322843723,7/14/2014 13:32:22,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],its pathophysiological function,N/A,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 13:40:09,,1322849166,7/14/2014 13:39:27,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],function in,na,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 13:47:06,,1322854372,7/14/2014 13:46:31,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],pathophysiological function,n/a,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 13:58:39,,1322862345,7/14/2014 13:57:54,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],but its function in,N/A,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 14:07:03,,1322868163,7/14/2014 14:06:37,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],pathophysiological function in,n/a,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 14:21:47,,1322878121,7/14/2014 14:21:35,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[LOCATION],[LOCATION],SYSTEMIC,N/A,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 14:22:04,,1322878331,7/14/2014 14:20:49,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[SYMPTOM],[SYMPTOM],SYSTEMIC INFLAMMATORY RESPONSE SYNDROME function in SEPSIS is unclear.,N/A,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 14:28:02,,1322882594,7/14/2014 14:27:54,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],SYNDROME,N/A,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 14:28:44,,1322883120,7/14/2014 14:27:44,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],pathophysiological function,na,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912833,7/14/2014 14:29:24,,1322883613,7/14/2014 14:28:53,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],function in is unclear.,N/A,20,99,58,105,-1,RO-cause_of,900453-FS1,IL 19 is induced in SYSTEMIC INFLAMMATORY RESPONSE SYNDROME but its pathophysiological function in SEPSIS is unclear.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS
502912834,7/14/2014 12:53:19,,1322817041,7/14/2014 12:53:11,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],for,da,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 13:03:30,,1322823783,7/14/2014 13:02:42,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],obtain a TEST,N/A,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 13:22:32,,1322836748,7/14/2014 13:21:56,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],obtain,none,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 13:26:53,,1322839701,7/14/2014 13:25:51,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to detect,N/A,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 13:34:23,,1322844940,7/14/2014 13:34:05,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TEST,N/A,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 13:48:01,,1322855067,7/14/2014 13:47:06,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 14:05:12,,1322866897,7/14/2014 14:04:51,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION],[MANIFESTATION],modification,n/a,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 14:09:50,,1322869834,7/14/2014 14:09:13,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULOSIS PPD SKIN TEST,n/a,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 14:14:50,,1322873352,7/14/2014 14:13:36,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]",Anticipate reactivation TUBERCULOSIS obtain PPD SKIN TEST,N/A,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 14:16:28,,1322874434,7/14/2014 14:15:24,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],and obtain a PPD SKIN TEST,N/A,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 14:21:34,,1322877923,7/14/2014 14:21:24,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[MANIFESTATION],[MANIFESTATION],SKIN,N/A,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 14:33:40,,1322886688,7/14/2014 14:33:12,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",obtain a,NA,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 14:34:44,,1322887387,7/14/2014 14:34:03,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],obtain a,N/A,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 14:39:13,,1322890465,7/14/2014 14:39:06,instagc,1.0,27753923,GBR,"","",188.30.192.65,[MANIFESTATION],[MANIFESTATION],beginning,n/a,296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912834,7/14/2014 14:52:21,,1322898735,7/14/2014 14:51:53,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",obtain a,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],296,322,307,335,1,RO-may_diagnose,906759-FS1,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST
502912835,7/14/2014 13:14:50,,1322831382,7/14/2014 13:13:49,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[NONE],[NONE],n/a,Two seperate things with different causes each,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 13:15:06,,1322831599,7/14/2014 13:14:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],EPITHELIAL,N/A,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 13:38:56,,1322848263,7/14/2014 13:38:38,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 13:45:46,,1322853151,7/14/2014 13:45:17,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 13:53:54,,1322859171,7/14/2014 13:51:28,clixsense,1.0,19294877,USA,MA,Boston,140.241.0.20,[NONE],[NONE],N/A,It is impossible to make a true connection based on the wording,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 14:03:04,,1322865549,7/14/2014 14:02:08,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],varying intensity patients,n/a,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 14:05:37,,1322867172,7/14/2014 14:04:54,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 14:07:04,,1322868189,7/14/2014 14:06:52,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],intensity,Na,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 14:17:50,,1322875332,7/14/2014 14:17:12,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],EPITHELIAL DYSPLASIA EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,n/a,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 14:21:23,,1322877788,7/14/2014 14:21:12,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[PART_OF],[PART_OF],varying,N/A,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 14:21:49,,1322878162,7/14/2014 14:20:16,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 14:25:50,,1322881024,7/14/2014 14:25:41,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],patients,N/A,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 14:31:23,,1322885159,7/14/2014 14:31:06,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],control group.,N/A,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 14:39:22,,1322890588,7/14/2014 14:39:14,instagc,1.0,27753923,GBR,"","",188.30.192.65,[PREVENTS],[PREVENTS],EPITHELIAL DYSPLASIA,n/a,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912835,7/14/2014 14:49:57,,1322897330,7/14/2014 14:48:40,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],EPITHELIAL DYSPLASIA varying in 36 patients EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA in 9 patients control group.,N/A,77,16,116,36,-1,RO-disease_has_finding,901503-FS1,It was revealed EPITHELIAL DYSPLASIA varying in intensity in 36 patients and EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA (acanthosis) in 9 patients  control group.,EPITHELIAL HYPERPLASIA WITHOUT DYSPLASIA,EPITHELIAL DYSPLASIA
502912836,7/14/2014 12:51:26,,1322815700,7/14/2014 12:51:19,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],positive,da,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 13:13:59,,1322830848,7/14/2014 13:13:46,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],causative agent of,N/A,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 13:35:09,,1322845451,7/14/2014 13:34:51,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],is a,N/A,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 14:04:12,,1322866257,7/14/2014 14:03:56,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],causative agent,n/a,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 14:04:16,,1322866337,7/14/2014 14:03:47,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CAUSES],[CAUSES],that is the causative agent of,N/A,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 14:04:42,,1322866618,7/14/2014 14:04:27,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],is the causative agent of,N/a,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 14:08:58,,1322869321,7/14/2014 14:08:47,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],causative,Na,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 14:24:08,,1322879655,7/14/2014 14:23:46,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],causative agent of,N/A,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 14:28:31,,1322882929,7/14/2014 14:28:23,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],that,N/A,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 14:30:46,,1322884674,7/14/2014 14:30:33,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[CAUSES],[CAUSES],causative agent,N/A,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 14:38:17,,1322889843,7/14/2014 14:37:13,instagc,1.0,27753923,GBR,"","",188.30.192.65,[SYMPTOM],[SYMPTOM],Gram bacillus,n/a,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 14:48:19,,1322896370,7/14/2014 14:48:02,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[CAUSES],[CAUSES],BACILLUS ANTHRACIS ANTHRAX,n/a,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 14:51:26,,1322898212,7/14/2014 14:51:02,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],is the causative,[CAUSES],0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 14:54:03,,1322899744,7/14/2014 14:53:46,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],causative agent of,N/A,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912836,7/14/2014 14:57:22,,1322901921,7/14/2014 14:57:03,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],causative agent,N/A,0,78,17,85,1,RO-has_causative_agent,903926-FS1,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
502912837,7/14/2014 13:02:10,,1322822913,7/14/2014 13:01:13,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],response to,N/A,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 13:28:35,,1322840821,7/14/2014 13:27:56,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],dose response to,na,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 13:36:25,,1322846428,7/14/2014 13:35:49,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],was determined by,N/A,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 14:01:25,,1322864404,7/14/2014 14:00:55,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],a dose response to,N/a,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 14:06:12,,1322867629,7/14/2014 14:05:57,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],dose response to,n/a,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 14:22:13,,1322878415,7/14/2014 14:22:00,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[PREVENTS],[PREVENTS],MALIGNANT,N/A,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 14:27:01,,1322881817,7/14/2014 14:26:54,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],HYPERTHERMIA,N/A,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 14:41:16,,1322891851,7/14/2014 14:41:02,instagc,1.0,27753923,GBR,"","",188.30.192.65,[MANIFESTATION],[MANIFESTATION],group sensitive,n/a,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 14:42:37,,1322892784,7/14/2014 14:41:54,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],dose response,na,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 14:49:00,,1322896743,7/14/2014 14:48:36,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was determined by,[DIAGNOSE_BY_TEST_OR_DRUG],39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 14:52:16,,1322898676,7/14/2014 14:51:54,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MALIGNANT HYPERTHERMIA (MHS) INTRAVENOUS DANTROLENE,n/a,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 14:52:18,,1322898714,7/14/2014 14:51:11,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation,N/A,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 14:53:44,,1322899581,7/14/2014 14:53:27,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],dose response,N/A,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 14:56:25,,1322901225,7/14/2014 14:55:59,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],a dose response,N/A,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912837,7/14/2014 15:00:07,,1322903579,7/14/2014 14:59:05,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.26,[TREATS],[TREATS],dose,N/A,39,87,60,109,1,RO-may_treat,908181-FS1,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
502912838,7/14/2014 12:50:56,,1322815397,7/14/2014 12:50:49,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],illustrate,da,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 13:17:29,,1322833258,7/14/2014 13:16:48,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],illustrate the key role of,n/a,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 13:25:29,,1322838703,7/14/2014 13:24:55,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[PREVENTS],[PREVENTS],key role of,na,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 13:35:35,,1322845775,7/14/2014 13:35:08,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],Diseases associated,none,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 13:35:48,,1322845931,7/14/2014 13:35:10,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated to,N/A,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 14:05:33,,1322867118,7/14/2014 14:05:17,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],deficiency,Na,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 14:06:12,,1322867626,7/14/2014 14:05:48,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PREVENTS],[PREVENTS],Vitamin D deficiency,N/a,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 14:14:32,,1322873090,7/14/2014 14:13:35,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],illustrate the key role,N/A,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 14:15:24,,1322873697,7/14/2014 14:14:19,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PREVENTS],[PREVENTS],the key role of VITAMIN D calcium homeostasis and bone metabolism.,N/A,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 14:19:16,,1322876333,7/14/2014 14:19:01,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],INHERITED RICKETS VITAMIN D,N/A,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 14:27:16,,1322882079,7/14/2014 14:26:58,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[PREVENTS],[PREVENTS],the key role,N/A,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 14:28:40,,1322883092,7/14/2014 14:28:31,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],"children, of",N/A,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 14:29:40,,1322883854,7/14/2014 14:29:14,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated to of,na,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 14:44:27,,1322894053,7/14/2014 14:44:18,instagc,1.0,27753923,GBR,"","",188.30.192.65,[SIDE_EFFECT],[SIDE_EFFECT],VITAMIN calcium,n/a,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912838,7/14/2014 14:48:39,,1322896598,7/14/2014 14:47:12,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[SYMPTOM],[SYMPTOM],"Vitamin deficiency (rickets in children, D",N/A,143,188,159,197,1,RO-may_treat,908221-FS1,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
502912839,7/14/2014 12:52:27,,1322816470,7/14/2014 12:52:21,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],DYSPLASIA,da,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 13:33:00,,1322843967,7/14/2014 13:32:47,zoombucks,1,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],treatment,N/A,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 13:39:24,,1322848568,7/14/2014 13:38:55,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],following treatment for,na,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 14:00:19,,1322863518,7/14/2014 13:59:35,neodev,1,12115558,USA,OH,Twinsburg,75.187.196.41,[SIDE_EFFECT],[SIDE_EFFECT],following treatment for,N/A,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 14:07:36,,1322868553,7/14/2014 14:07:20,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],treatment,Na,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 14:08:11,,1322868885,7/14/2014 14:07:51,instagc,1,18960682,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],Untreated following treatment for,N/a,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 14:13:32,,1322872518,7/14/2014 14:13:16,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],following treatment for,n/a,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 14:17:06,,1322874833,7/14/2014 14:16:31,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],ACETABULAR DYSPLASIA DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH),n/a,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 14:20:43,,1322877367,7/14/2014 14:20:31,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,[CONTRAINDICATES],[CONTRAINDICATES],DEVELOPMENTAL,N/A,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 14:24:44,,1322880214,7/14/2014 14:24:08,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],following treatment for,N/A,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 14:27:33,,1322882223,7/14/2014 14:27:17,instagc,1,28301350,GBR,K4,Plymouth,78.145.138.150,[SIDE_EFFECT],[SIDE_EFFECT],following treatment,N/A,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 14:29:13,,1322883441,7/14/2014 14:28:46,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[TREATS],[TREATS],treatment for,na,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 14:41:54,,1322892288,7/14/2014 14:40:34,clixsense,1,8100278,USA,FL,Orlando,98.70.77.97,[SYMPTOM],[SYMPTOM],Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP leads to early degenerative joint disease.,N/A,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 14:43:26,,1322893294,7/14/2014 14:43:16,instagc,1.0,27753923,GBR,"","",188.30.192.65,[PREVENTS],[PREVENTS],DEVELOPMENTAL DYSPLASIA,n/a,55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912839,7/14/2014 14:49:30,,1322897009,7/14/2014 14:49:01,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",treatment for,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],55,10,88,30,1,RO-has_manifestation,906484-FS1,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA
502912840,7/14/2014 12:50:48,,1322815267,7/14/2014 12:50:42,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was,da,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 13:09:41,,1322827921,7/14/2014 13:09:24,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in the relief of,N/A,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 13:13:22,,1322830503,7/14/2014 13:13:01,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],in the relief of,n/a,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 13:36:05,,1322846126,7/14/2014 13:35:52,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],relief,N/A,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 13:36:44,,1322846684,7/14/2014 13:35:55,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],daily dose of,na,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 13:37:53,,1322847477,7/14/2014 13:37:12,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],comparable with,N/A,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 13:49:28,,1322856100,7/14/2014 13:48:02,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",the relief of,n/a,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 14:05:28,,1322867027,7/14/2014 14:05:11,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],in the relief of,N/a,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 14:08:23,,1322869038,7/14/2014 14:08:09,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],daily dose relief,Na,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 14:13:25,,1322872431,7/14/2014 14:10:41,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],in the relief of,N/A,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 14:20:20,,1322877031,7/14/2014 14:20:08,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MG,N/A,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 14:24:17,,1322879754,7/14/2014 14:24:08,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SYMPTOM],[SYMPTOM],efficacy,N/A,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 14:30:32,,1322884574,7/14/2014 14:30:17,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],in the relief,N/A,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 14:32:32,,1322885963,7/14/2014 14:31:08,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",Indoprofen at 900 MG OF IBUPROFEN relief of PAIN RELATED TO OSTEOARTHROSIS.,N/A,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912840,7/14/2014 14:43:15,,1322893190,7/14/2014 14:42:57,instagc,1.0,27753923,GBR,"","",188.30.192.65,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],600 comparable,n/a,108,71,137,90,1,RO-may_prevent,907332-FS1,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
502912841,7/14/2014 12:51:03,,1322815442,7/14/2014 12:50:57,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[LOCATION],[LOCATION],aldolase,da,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 12:58:55,,1322820818,7/14/2014 12:58:35,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],caused by,N/A,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 13:29:30,,1322841430,7/14/2014 13:28:53,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[CAUSES],[CAUSES],caused,none,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 13:38:45,,1322848173,7/14/2014 13:37:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],is caused by,N/A,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 13:39:19,,1322848542,7/14/2014 13:39:10,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[CAUSES],[CAUSES],caused,N/A,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 13:44:37,,1322852385,7/14/2014 13:44:03,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],caused by a,na,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 14:06:50,,1322868054,7/14/2014 14:06:34,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],caused,Na,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 14:09:30,,1322869638,7/14/2014 14:09:19,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],is caused by,N/a,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 14:12:10,,1322871469,7/14/2014 14:11:27,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[SYMPTOM],[SYMPTOM],FRUCTOSE INTOLERANCE caused by DEFICIT OF THE LIVER,N/A,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 14:14:19,,1322872910,7/14/2014 14:13:26,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],is caused by,N/A,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 14:14:29,,1322873071,7/14/2014 14:13:55,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],FRUCTOSE INTOLERANCE DEFICIT OF THE LIVER,n/a,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 14:22:26,,1322878533,7/14/2014 14:22:14,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[MANIFESTATION],[MANIFESTATION],INTOLERANCE,N/A,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 14:24:50,,1322880265,7/14/2014 14:24:42,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],INTOLERANCE,N/A,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 14:30:54,,1322884772,7/14/2014 14:29:41,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],caused by,na,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912841,7/14/2014 14:49:51,,1322897259,7/14/2014 14:49:06,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[CAUSES],[CAUSES],FRUCTOSE INTOLERANCE DEFICIT OF THE LIVER,n/a,36,0,55,20,-1,RO-has_manifestation,906249-FS1,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
502912842,7/14/2014 12:51:41,,1322815928,7/14/2014 12:51:35,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],persistent,da,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 13:13:18,,1322830454,7/14/2014 13:12:46,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],primary CDH such as,N/A,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 13:20:19,,1322835079,7/14/2014 13:19:30,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],subdivisions of primary,n/a,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 13:28:54,,1322841036,7/14/2014 13:28:19,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],have proposed,N/A,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 13:32:52,,1322843807,7/14/2014 13:32:21,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],subdivisions,none,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 13:40:08,,1322849161,7/14/2014 13:39:47,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],subdivisions,N/A,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 13:41:06,,1322849809,7/14/2014 13:40:38,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],subdivisions,na,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 14:08:39,,1322869166,7/14/2014 14:08:10,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],"transformed migraine,",n/a,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 14:15:13,,1322873571,7/14/2014 14:14:34,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],subdivisions of primary CDH such as,N/A,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 14:16:36,,1322874499,7/14/2014 14:14:51,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],proposed subdivisions of primary CDH such as EVOLVED MIGRAINE CHRONIC TENSION TYPE HEADACHE,N/A,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 14:21:57,,1322878261,7/14/2014 14:21:19,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],EVOLVED MIGRAINE CHRONIC TENSION TYPE HEADACHE,n/a,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 14:23:37,,1322879331,7/14/2014 14:23:26,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CDH,N/A,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 14:23:57,,1322879583,7/14/2014 14:23:27,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],"transformed migraine,",na,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 14:26:10,,1322881196,7/14/2014 14:26:02,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],hemicrania,N/A,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912842,7/14/2014 14:36:24,,1322888575,7/14/2014 14:34:48,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE",N/A,123,84,151,100,-1,RO-has_definitional_manifestation,904504-FS1,"Several authors have proposed subdivisions of primary CDH such as chronic migraine, EVOLVED MIGRAINE transformed migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and hemicrania continua.",CHRONIC TENSION TYPE HEADACHE,EVOLVED MIGRAINE
502912843,7/14/2014 12:53:44,,1322817384,7/14/2014 12:53:38,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[SYMPTOM],[SYMPTOM],the,da,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 13:26:14,,1322839298,7/14/2014 13:25:30,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as in some cases,na,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 13:34:38,,1322845150,7/14/2014 13:34:07,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],seen,none,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 14:03:14,,1322865718,7/14/2014 14:02:38,instagc,1.0,18960682,GBR,"","",86.29.147.112,[NONE],[NONE],N/a,They are different diseases,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 14:05:41,,1322867193,7/14/2014 14:05:05,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],POLYCYTHAEMIA VERA THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,n/a,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 14:06:48,,1322868016,7/14/2014 14:06:18,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],well as in some cases,N/A,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 14:09:50,,1322869835,7/14/2014 14:09:21,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],well in some cases,n/a,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 14:19:35,,1322876535,7/14/2014 14:19:17,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],POLYCYTHAEMIA VERA THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,N/A,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 14:25:41,,1322880963,7/14/2014 14:25:31,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],myelofibrosis.,N/A,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 14:43:36,,1322893504,7/14/2014 14:43:27,instagc,1.0,27753923,GBR,"","",188.30.192.65,[PREVENTS],[PREVENTS],(EEC) are,n/a,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 14:48:08,,1322896246,7/14/2014 14:46:27,clixsense,1.0,19294877,USA,MA,Boston,140.241.0.20,[OTHER],[OTHER],POLYCYTHAEMIA VERA as well as CHRONIC MYELOID LEUKAEMIA,N/A,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 14:51:53,,1322898431,7/14/2014 14:51:27,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",POLYCYTHAEMIA VERA THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,n/a,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 14:54:26,,1322899963,7/14/2014 14:54:04,instagc,1,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,N/A,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 14:54:47,,1322900253,7/14/2014 14:54:21,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",in some cases of,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912843,7/14/2014 14:59:00,,1322902884,7/14/2014 14:58:13,instagc,1,28519532,USA,IA,Honey Creek,12.73.110.26,[ASSOCIATED_WITH],[ASSOCIATED_WITH],seen in as well as,N/A,132,85,173,103,-1,RO-has_manifestation,906409-FS1,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
502912844,7/14/2014 13:05:59,,1322825351,7/14/2014 13:05:45,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],differs,Na,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 13:22:14,,1322836508,7/14/2014 13:21:48,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],more frequent occurrence of MIGRAINE,n/a,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 13:59:34,,1322863046,7/14/2014 13:58:40,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],differs from of more frequent occurrence,N/A,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 14:05:56,,1322867383,7/14/2014 14:05:26,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",more frequent occurrence of,n/a,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 14:12:29,,1322871741,7/14/2014 14:11:53,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[PART_OF],[PART_OF],TENSION TYPE HEADACHE MIGRAINE,n/a,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 14:26:21,,1322881361,7/14/2014 14:25:38,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],Migraine with,N/A,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 14:34:02,,1322886936,7/14/2014 14:33:42,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],differs from,N/A,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 14:41:01,,1322891718,7/14/2014 14:40:40,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CAUSES],[CAUSES],TENSION TYPE HEADACHE,n/a,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 14:49:52,,1322897274,7/14/2014 14:48:53,clixsense,1.0,21406414,USA,NY,Spencerport,50.122.189.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,it is associated with,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 14:50:12,,1322897466,7/14/2014 14:49:21,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[IS_A],[IS_A],Migraine with,N/A,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 14:51:25,,1322898166,7/14/2014 14:50:59,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TENSION TYPE HEADACHE MIGRAINE,n/a,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 14:52:04,,1322898524,7/14/2014 14:51:37,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],HEADACHE MIGRAINE,N/A,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 14:55:17,,1322900530,7/14/2014 14:54:49,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]",differs from,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [SYMPTOM],14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 14:57:01,,1322901743,7/14/2014 14:56:26,vivatic,1,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],with,N/A,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912844,7/14/2014 14:58:08,,1322902372,7/14/2014 14:57:28,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.26,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Migraine with differs,N/A,14,163,34,171,-1,RO-has_definitional_manifestation,904906-FS1,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
502912845,7/14/2014 12:52:05,,1322816221,7/14/2014 12:51:57,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],"Crouzon,",da,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 13:07:46,,1322826613,7/14/2014 13:07:08,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized by,N/A,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 13:27:31,,1322840158,7/14/2014 13:26:41,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],characterized,none,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 13:33:15,,1322844146,7/14/2014 13:33:01,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 13:33:52,,1322844505,7/14/2014 13:32:02,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],characterized by,N/A,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 13:45:00,,1322852578,7/14/2014 13:44:23,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 13:51:26,,1322857510,7/14/2014 13:49:54,clixsense,1.0,19294877,USA,MA,Boston,140.241.0.20,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized by CRANIOFACIAL DYSOSTOSIS and DIVERGENT SQUINT,N/A,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 14:07:49,,1322868653,7/14/2014 14:07:24,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",characterized by hypertelorism,n/a,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 14:16:26,,1322874409,7/14/2014 14:15:48,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CRANIOFACIAL DYSOSTOSIS DIVERGENT SQUINT,n/a,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 14:20:57,,1322877500,7/14/2014 14:20:44,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[TREATS],[TREATS],CRANIOFACIAL,N/A,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 14:23:46,,1322879442,7/14/2014 14:23:14,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 14:39:31,,1322890667,7/14/2014 14:39:23,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CONTRAINDICATES],[CONTRAINDICATES],CRANIOFACIAL DYSOSTOSIS,n/a,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 14:44:58,,1322894375,7/14/2014 14:43:55,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[SYMPTOM],[SYMPTOM],Crouzon's disease characterized by CRANIOFACIAL DYSOSTOSIS and DIVERGENT SQUINT,N/A,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 14:46:34,,1322895348,7/14/2014 14:46:00,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],"exophthalmos, optic",na,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912845,7/14/2014 14:57:18,,1322901881,7/14/2014 14:56:52,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CRANIOFACIAL DYSOSTOSIS DIVERGENT SQUINT,n/a,253,196,268,219,-1,RO-has_manifestation,906130-FS1,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
502912846,7/14/2014 13:05:28,,1322824937,7/14/2014 13:05:15,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],administration,Na,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 13:12:45,,1322829943,7/14/2014 13:12:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[PREVENTS],[PREVENTS],prevented the development of,N/A,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 13:22:32,,1322836759,7/14/2014 13:21:26,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],reduced,N/A,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 13:24:02,,1322837793,7/14/2014 13:23:44,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PREVENTS],[PREVENTS],significantly reduced prevented,n/a,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 13:37:39,,1322847330,7/14/2014 13:36:55,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],administration,N/A,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 14:02:11,,1322864960,7/14/2014 14:01:52,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",significantly reduced infarct size and prevented,N/a,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 14:04:31,,1322866472,7/14/2014 14:04:13,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],prevented development,n/a,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 14:12:11,,1322871474,7/14/2014 14:11:35,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PREVENTS],[PREVENTS],significantly reduced infarct size and prevented the development,N/A,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 14:18:25,,1322875644,7/14/2014 14:18:06,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],RAMIPRIL LEFT VENTRICULAR HYPERTROPHY,N/A,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 14:25:16,,1322880594,7/14/2014 14:25:00,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],administration,N/A,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 14:26:32,,1322881481,7/14/2014 14:25:48,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[PREVENTS],[PREVENTS],prevented,na,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 14:26:34,,1322881510,7/14/2014 14:26:21,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],administration,N/A,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 14:40:57,,1322891711,7/14/2014 14:40:26,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PREVENTS],[PREVENTS],prevented the development of,N/A,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 14:42:10,,1322892527,7/14/2014 14:42:01,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CAUSES],[CAUSES],VENTRICULAR HYPERTROPHY,n/a,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912846,7/14/2014 14:47:11,,1322895742,7/14/2014 14:46:10,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[PREVENTS],[PREVENTS],RAMIPRIL significantly reduced infarct size and prevented LEFT VENTRICULAR HYPERTROPHY,N/A,147,55,174,63,1,RO-may_prevent,907265-FS1,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL
502912847,7/14/2014 12:49:57,,1322814663,7/14/2014 12:49:50,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],which,da,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 13:07:32,,1322826395,7/14/2014 13:07:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],all,Na,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 13:11:06,,1322828845,7/14/2014 13:10:36,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],developed in all,n/a,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 13:14:42,,1322831275,7/14/2014 13:14:28,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],in all,N/A,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 13:23:01,,1322837134,7/14/2014 13:22:33,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],developed in,N/A,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 13:25:59,,1322839081,7/14/2014 13:25:31,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],developed,none,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 13:39:47,,1322848880,7/14/2014 13:39:20,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],developed,N/A,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 14:07:22,,1322868379,7/14/2014 14:06:49,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],developed in all,N/A,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 14:08:09,,1322868888,7/14/2014 14:07:50,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],developed,n/a,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 14:09:42,,1322869748,7/14/2014 14:09:31,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],developed in all,N/a,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 14:20:49,,1322877442,7/14/2014 14:19:55,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[LOCATION] [IS_A],"[LOCATION]
[IS_A]",ARTHRITIS developed in all JOINTS,N/A,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 14:21:59,,1322878278,7/14/2014 14:21:48,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[LOCATION],[LOCATION],JOINTS,N/A,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 14:28:22,,1322882808,7/14/2014 14:28:13,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],prosthesis,N/A,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 14:32:03,,1322885671,7/14/2014 14:31:49,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[LOCATION],[LOCATION],in all,N/A,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912847,7/14/2014 14:36:31,,1322888613,7/14/2014 14:35:30,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],developed in,na,27,0,32,9,1,RO-disease_has_primary_anatomic_site,902293-FS1,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
502912848,7/14/2014 12:58:33,,1322820591,7/14/2014 12:57:06,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],HYPERSENSITIVITY,N/A,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 13:15:35,,1322831890,7/14/2014 13:15:16,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],cause of asthma,n/a,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 13:24:21,,1322838032,7/14/2014 13:23:54,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[CAUSES],[CAUSES],cause,none,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 13:27:22,,1322840047,7/14/2014 13:26:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],is a,N/A,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 13:27:53,,1322840321,7/14/2014 13:27:18,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CAUSES],[CAUSES],triggering factor,na,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 13:32:21,,1322843318,7/14/2014 13:31:59,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],nonetheless,N/A,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 14:05:10,,1322866891,7/14/2014 14:04:43,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],significant triggering factor,N/a,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 14:08:29,,1322869100,7/14/2014 14:07:55,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],ALLERGY HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,n/a,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 14:08:59,,1322869325,7/14/2014 14:08:40,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],triggering factor,n/a,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 14:23:26,,1322879171,7/14/2014 14:23:15,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ALLERGY,N/A,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 14:29:03,,1322883318,7/14/2014 14:28:53,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],asthma,N/A,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 14:29:27,,1322883656,7/14/2014 14:27:45,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[CAUSES],[CAUSES],ALLERGY of asthma HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS factor in,N/A,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 14:31:48,,1322885482,7/14/2014 14:31:24,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],not sole cause,N/A,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 14:37:42,,1322889442,7/14/2014 14:36:24,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],is a significant triggering factor,N/A,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912848,7/14/2014 14:39:50,,1322890937,7/14/2014 14:38:13,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],significant triggering factor,na,76,20,118,27,-1,RO-cause_of,900033-FS1,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY
502912849,7/14/2014 13:06:27,,1322825644,7/14/2014 13:05:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],general complication of,N/A,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 13:21:19,,1322835808,7/14/2014 13:20:55,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],general complication of,n/a,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 13:30:58,,1322842452,7/14/2014 13:30:43,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[IS_A],[IS_A],is a,N/A,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 13:37:10,,1322846929,7/14/2014 13:36:50,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],and,none,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 13:41:24,,1322850036,7/14/2014 13:41:05,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],is a,N/A,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 14:03:46,,1322865963,7/14/2014 14:03:01,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SIDE_EFFECT],[SIDE_EFFECT],is a general complication of chronic,N/A,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 14:05:47,,1322867268,7/14/2014 14:05:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],general complication of,N/a,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 14:06:33,,1322867825,7/14/2014 14:06:20,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],complication,Na,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 14:09:21,,1322869575,7/14/2014 14:09:00,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION],[MANIFESTATION],complication of chronic,n/a,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 14:27:13,,1322882003,7/14/2014 14:27:02,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],chronic,N/A,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 14:32:24,,1322885890,7/14/2014 14:32:04,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[CAUSES],[CAUSES],is a complication,N/A,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 14:42:46,,1322892899,7/14/2014 14:42:11,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CAUSES],[CAUSES],RENAL OSTEODYSTROPHY,n/a,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 14:47:00,,1322895641,7/14/2014 14:46:36,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],complication of chronic renal failure,na,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 14:51:01,,1322897936,7/14/2014 14:49:58,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",a general complication of,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912849,7/14/2014 14:53:27,,1322899399,7/14/2014 14:53:07,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],general complication of,N/A,0,76,19,99,1,RO-cause_of,900397-FS1,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
502912850,7/14/2014 12:53:37,,1322817332,7/14/2014 12:53:28,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],alpha,da,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 13:21:47,,1322836178,7/14/2014 13:21:20,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],of a patient with,n/a,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 13:24:16,,1322838005,7/14/2014 13:23:02,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],were compared.,N/A,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 13:31:33,,1322842767,7/14/2014 13:31:17,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 13:42:05,,1322850495,7/14/2014 13:41:37,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[LOCATION],[LOCATION],and from,na,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 14:06:16,,1322867671,7/14/2014 14:05:38,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],and from ASCITES of patient with,N/A,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 14:06:36,,1322867858,7/14/2014 14:06:13,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],of a patient with,n/a,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 14:07:01,,1322868131,7/14/2014 14:06:47,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],of a patient with,N/a,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 14:07:49,,1322868672,7/14/2014 14:07:09,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASCITES FLUID HEPATOMA,n/a,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 14:08:08,,1322868876,7/14/2014 14:07:52,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],from patient,Na,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 14:10:41,,1322870409,7/14/2014 14:09:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],were purified,N/A,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 14:22:45,,1322878731,7/14/2014 14:22:12,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],patient with,na,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 14:24:06,,1322879651,7/14/2014 14:23:56,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FLUID,N/A,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 14:26:57,,1322881779,7/14/2014 14:26:35,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],from,N/A,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912850,7/14/2014 14:27:44,,1322882337,7/14/2014 14:25:55,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA,N/A,74,106,86,114,1,RO-disease_may_have_finding,902852-FS1,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
502912851,7/14/2014 12:50:24,,1322814977,7/14/2014 12:50:16,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[SYMPTOM],[SYMPTOM],the,da,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 13:22:34,,1322836801,7/14/2014 13:22:16,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or not discolored,n/a,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 13:28:51,,1322841006,7/14/2014 13:28:10,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],urine,none,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 13:34:50,,1322845245,7/14/2014 13:33:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],may be,N/A,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 13:38:37,,1322848028,7/14/2014 13:38:10,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[SYMPTOM],[SYMPTOM],may be,N/A,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 13:42:35,,1322850904,7/14/2014 13:42:07,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or not discolored,na,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 13:44:21,,1322852198,7/14/2014 13:43:51,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or not,n/a,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 14:05:00,,1322866809,7/14/2014 14:04:17,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],(GROSS HEMATURIA) (MICROSCOPIC HEMATURIA).,n/a,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 14:10:26,,1322870224,7/14/2014 14:10:01,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],Hematuria is,N/a,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 14:12:48,,1322871965,7/14/2014 14:12:16,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT],[SIDE_EFFECT],the urine may be red,n/a,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 14:23:55,,1322879557,7/14/2014 14:23:38,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CONTRAINDICATES],[CONTRAINDICATES],RBCs,N/A,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 14:26:40,,1322881607,7/14/2014 14:26:31,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],(macroscopic,N/A,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 14:30:16,,1322884337,7/14/2014 14:29:45,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],bloody or not,N/A,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 14:34:48,,1322887437,7/14/2014 14:34:07,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],bloody or not discolored,N/A,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912851,7/14/2014 14:35:29,,1322887933,7/14/2014 14:33:42,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Hematuria is,na,102,138,116,159,-1,RO-has_definitional_manifestation,904998-FS1,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA
502912852,7/14/2014 12:52:20,,1322816396,7/14/2014 12:52:14,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],in,da,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 13:08:30,,1322827177,7/14/2014 13:08:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],frequent,Na,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 13:14:27,,1322831190,7/14/2014 13:14:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],frequent finding in patients presenting with,N/A,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 13:23:19,,1322837471,7/14/2014 13:22:50,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],very frequent finding in,n/a,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 13:28:08,,1322840488,7/14/2014 13:27:34,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],finding,none,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 13:30:53,,1322842417,7/14/2014 13:29:53,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],frequent finding,na,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 13:46:31,,1322853826,7/14/2014 13:45:57,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients presenting with,n/a,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 14:04:26,,1322866429,7/14/2014 14:04:10,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],very frequent finding in patients presenting with,N/a,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 14:09:08,,1322869433,7/14/2014 14:08:34,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],HYPERTENSION WILMS' TUMOR,n/a,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 14:24:07,,1322879652,7/14/2014 14:22:45,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],finding,N/A,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 14:28:17,,1322882728,7/14/2014 14:27:30,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],is a very frequent finding in patients presenting with,N/A,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 14:34:58,,1322887506,7/14/2014 14:34:45,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[SYMPTOM],[SYMPTOM],frequent finding,N/A,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 14:43:46,,1322893605,7/14/2014 14:43:38,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CAUSES],[CAUSES],HYPERTENSION is,n/a,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 14:43:54,,1322893723,7/14/2014 14:43:18,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[SYMPTOM],[SYMPTOM],HYPERTENSION finding in patients with WILMS' TUMOR,N/A,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912852,7/14/2014 14:47:42,,1322896042,7/14/2014 14:47:15,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[SYMPTOM],[SYMPTOM],HYPERTENSION WILMS' TUMOR,n/a,0,68,11,80,1,RO-disease_may_have_finding,902898-FS1,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502912853,7/14/2014 13:06:32,,1322825711,7/14/2014 13:06:21,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],suggesting,Na,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 13:32:17,,1322843257,7/14/2014 13:31:49,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,none,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 13:38:10,,1322847669,7/14/2014 13:37:57,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],indicator,N/A,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 14:03:08,,1322865572,7/14/2014 14:02:24,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],UNFAVORABLE CLINICAL OUTCOME OVARIAN CARCINOMA,n/a,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 14:03:54,,1322866060,7/14/2014 14:03:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],correlated with,N/a,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 14:20:30,,1322877150,7/14/2014 14:20:21,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[LOCATION],[LOCATION],LAPTM4B,N/A,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 14:36:06,,1322888366,7/14/2014 14:35:36,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[SYMPTOM],[SYMPTOM],useful prognostic indicator,N/A,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 14:40:33,,1322891397,7/14/2014 14:39:10,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],high LAPTM4B was associated with progression of and with UNFAVORABLE CLINICAL OUTCOME OVARIAN CARCINOMA,N/A,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 14:40:38,,1322891458,7/14/2014 14:40:12,instagc,1.0,27753923,GBR,"","",188.30.192.65,[PREVENTS],[PREVENTS],LAPTM4B may,n/a,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 14:42:50,,1322892941,7/14/2014 14:42:10,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],may be a clinically useful prognostic indicator for,N/A,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 14:53:06,,1322899219,7/14/2014 14:52:37,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 14:53:38,,1322899494,7/14/2014 14:53:05,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",UNFAVORABLE CLINICAL OUTCOME OVARIAN CARCINOMA,n/a,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 14:53:56,,1322899664,7/14/2014 14:53:25,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]",may be clinically useful,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS],123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 14:58:51,,1322902798,7/14/2014 14:57:23,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],N/A,"The relationship is with the drug, not the unfavourable outcome.",123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912853,7/14/2014 14:59:51,,1322903421,7/14/2014 14:58:38,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlated,N/A,123,228,150,245,1,RO-disease_may_have_finding,902537-FS1,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA
502912854,7/14/2014 12:52:35,,1322816517,7/14/2014 12:52:28,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],their,da,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 12:59:47,,1322821335,7/14/2014 12:58:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],DRUG,N/A,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 13:07:48,,1322826620,7/14/2014 13:07:34,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],frequency,Na,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 13:18:43,,1322834083,7/14/2014 13:18:15,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PREVENTS],[PREVENTS],frequency of,n/a,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 13:35:51,,1322845972,7/14/2014 13:35:32,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[SIDE_EFFECT],[SIDE_EFFECT],SIDE EFFECTS,N/A,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 13:41:04,,1322849795,7/14/2014 13:40:04,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],to determine,N/A,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 13:50:26,,1322856716,7/14/2014 13:49:29,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],frequency of,n/a,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 14:10:10,,1322870039,7/14/2014 14:09:51,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT],[SIDE_EFFECT],frequency of,n/a,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 14:11:09,,1322870745,7/14/2014 14:10:38,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DRUG REGIMENS DRUG SIDE EFFECTS,n/a,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 14:18:42,,1322875870,7/14/2014 14:18:26,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],DRUG REGIMENS DRUG SIDE EFFECTS,N/A,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 14:28:52,,1322883209,7/14/2014 14:28:41,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SIDE_EFFECT],[SIDE_EFFECT],"condition,",N/A,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 14:37:34,,1322889291,7/14/2014 14:35:24,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compliance to DRUG REGIMENS of DRUG SIDE EFFECTS and frequency,N/A,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 14:40:45,,1322891536,7/14/2014 14:40:20,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],frequency,na,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 14:46:26,,1322895288,7/14/2014 14:45:41,clixsense,1.0,19294877,USA,MA,Boston,140.241.0.20,[SIDE_EFFECT],[SIDE_EFFECT],DRUG REGIMENS frequency of DRUG SIDE EFFECTS,N/A,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912854,7/14/2014 14:51:10,,1322898042,7/14/2014 14:50:13,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[SIDE_EFFECT],[SIDE_EFFECT],side effects,N/A,240,267,252,284,-1,RO-has_causative_agent,903825-FS1,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS
502912855,7/14/2014 12:51:34,,1322815831,7/14/2014 12:51:27,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],for,da,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 13:05:14,,1322824764,7/14/2014 13:05:00,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],biomarker,Na,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 13:11:58,,1322829462,7/14/2014 13:11:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],such as,N/A,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 13:23:51,,1322837694,7/14/2014 13:23:08,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such as,none,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 13:38:54,,1322848235,7/14/2014 13:37:22,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],such as,na,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 14:03:28,,1322865792,7/14/2014 14:03:15,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],such as,N/a,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 14:14:14,,1322872877,7/14/2014 14:13:33,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],biomarker such as,n/a,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 14:16:16,,1322874320,7/14/2014 14:15:14,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],predictive of specific such as PREECLAMPSIA,N/A,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 14:19:50,,1322876702,7/14/2014 14:19:16,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PREGNANCY COMPLICATIONS PREECLAMPSIA,n/a,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 14:22:52,,1322878795,7/14/2014 14:22:38,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[IS_A],[IS_A],PLAC1,N/A,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 14:27:43,,1322882336,7/14/2014 14:27:35,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],biomarker,N/A,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 14:28:17,,1322882729,7/14/2014 14:27:57,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[SYMPTOM],[SYMPTOM],such as,N/A,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 14:35:23,,1322887877,7/14/2014 14:34:00,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[SYMPTOM],[SYMPTOM],PREGNANCY COMPLICATIONS such as PREECLAMPSIA,N/A,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 14:38:48,,1322890215,7/14/2014 14:38:41,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CAUSES],[CAUSES],PREGNANCY COMPLICATIONS,n/a,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912855,7/14/2014 14:55:14,,1322900518,7/14/2014 14:54:39,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PREGNANCY COMPLICATIONS PREECLAMPSIA,n/a,81,113,103,125,-1,RO-disease_has_finding,901889-FS1,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
502912856,7/14/2014 12:52:52,,1322816715,7/14/2014 12:52:44,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[MANIFESTATION],[MANIFESTATION],of,da,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 13:10:10,,1322828310,7/14/2014 13:09:42,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BERYLLIUM,N/A,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 13:23:41,,1322837611,7/14/2014 13:23:21,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],low prevalence of,n/a,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 13:30:24,,1322842050,7/14/2014 13:30:00,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],associated,none,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 13:36:54,,1322846787,7/14/2014 13:36:36,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated and,N/A,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 14:03:55,,1322866066,7/14/2014 14:03:24,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 14:04:09,,1322866232,7/14/2014 14:03:55,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is associated with,N/a,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 14:13:35,,1322872573,7/14/2014 14:12:11,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],beryl containing gemstones is associated with development BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE,N/A,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 14:17:54,,1322875350,7/14/2014 14:17:22,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],is associated with development of,N/A,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 14:22:38,,1322878660,7/14/2014 14:22:27,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Inhalation,N/A,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 14:22:43,,1322878729,7/14/2014 14:21:51,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and low prevalence of,N/A,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 14:25:00,,1322880400,7/14/2014 14:24:52,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],beryl,N/A,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 14:33:41,,1322886703,7/14/2014 14:33:21,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BERYLLIUM BERYLLIUM,N/A,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 14:39:45,,1322890870,7/14/2014 14:39:32,instagc,1.0,27753923,GBR,"","",188.30.192.65,[IS_A],[IS_A],dusts generated,n/a,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
502912856,7/14/2014 14:40:18,,1322891238,7/14/2014 14:39:51,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[LOCATION],[LOCATION],low prevalence of,na,139,185,161,210,-1,RO-has_causative_agent,903627-FS1,Inhalation of beryllium dusts generated during milling of ores and cutting of beryl containing gemstones is associated with development of BERYLLIUM SENSITIZATION and low prevalence of CHRONIC BERYLLIUM DISEASE (CBD.,BERYLLIUM SENSITIZATION,CHRONIC BERYLLIUM DISEASE
